Five biomarkers improve risk assessment for adverse outcomes in ischemic stroke patients

Takeaway

  • Considering levels of high-sensitivity C-reactive protein (hsCRP), complement C3, matrix metalloproteinase-9 (MMP-9), hepatocyte growth factor (HGF), and antiphosphatidylserine antibodies (aPS) in addition to established stroke risk factors could significantly improve risk assessment for adverse outcomes in ischemic stroke patients.

Why this matters

    Established stroke risk factors do not fully reflect pathophysiologic pathways and outcomes.